<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312087</url>
  </required_header>
  <id_info>
    <org_study_id>TC-MAP</org_study_id>
    <nct_id>NCT04312087</nct_id>
  </id_info>
  <brief_title>Lateral Neck Lymph Node Mapping in Thyroid Cancer</brief_title>
  <official_title>Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes papillary thyroid cancer patients who have unpalpable lateral neck lymph
      nodes but suspicious on ultrasound and/or CT. Carbon nanoparticles is used as the tracer for
      lateral neck lymph node mapping.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymph node counts</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Dyed versus undyed lymph node counts in lateral neck compartments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymph node metastasis rate</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>The rate of lymph node metastasis in lateral neck compartments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>MLND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified lateral neck dissection (compartment II-V) is performed in all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lateral neck sentinel lymph node biopsy</intervention_name>
    <description>Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.</description>
    <arm_group_label>SLNB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified lateral neck lymph node dissection</intervention_name>
    <description>Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).</description>
    <arm_group_label>MLND</arm_group_label>
    <arm_group_label>SLNB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Super selective lateral neck lymph node dissection</intervention_name>
    <description>Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).</description>
    <arm_group_label>SLNB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed papillary thyroid cancer

          -  The maximum diameter of the thyroid cancer &lt;3 cm with enough normal thyroid tissue for
             tracer injection

          -  Unpalpable lateral neck lymph nodes

          -  Ultrasound and CT showed suspected lateral neck lymph nodes &lt;2 cm

        Exclusion Criteria:

          -  Previously treated thyroid cancer

          -  High risk thyroid cancer (e.g. with severe extra-adenial invasion or extensive lymph
             node metastasis or poorly differentiated thyroid cancer)

          -  Patients with distant metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu Wang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>65805</phone_ext>
    <email>neck130@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-si Huang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>67816</phone_ext>
    <email>huangnaisi@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang, M.D.</last_name>
      <phone>86-021-64175590</phone>
      <phone_ext>65805</phone_ext>
      <email>neck130@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>lateral neck lymph node</keyword>
  <keyword>lymph node mapping</keyword>
  <keyword>neck dissection</keyword>
  <keyword>sentinel lymph node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

